Erythropoietin-stimulating agents — widely used to treat anemia in end-stage renal disease (ESRD) — increase the risk of hip fracture in patients on dialysis, and the higher the dose, the greater the ...
Efficacy of GM-CSF vs G-CSF in reducing chemotherapy-induced complications (CIC): A systematic review of literature ...
Please provide your email address to receive an email when new articles are posted on . Patients with sickle cell disease experiencing chronic anemia reported improved quality of life after adding ...
SAN FRANCISCO--(BUSINESS WIRE)--FibroGen, Inc., today announced proof-of-principle for oral anemia therapy FG-4592, a hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor (PHI), in end-stage ...
Tel Aviv, Israel - When anemia in CHF is treated with EPO and IV iron, a marked improvement in cardiac function is seen, associated with less hospitalization and renal impairment and less need for ...
Anemia in chronic kidney disease (CKD) causes the body to produce too few red blood cells. People with advanced kidney disease tend to develop this condition, and it can increase the risk of negative ...
Children with cancer who develop anemia during chemotherapy can benefit from a weekly dose of erythropoietin (EPO), according to researchers at St. Jude Children's Research Hospital. The drug reduces ...
After an FDA rejection, commercial disappointments in Europe and Japan and a clinical trial flop, FibroGen and AstraZeneca’s oral anemia drug Evrenzo has finally found a win back in China. In a phase ...
Source: Getty Images Addressing anemia in CKD requires a proactive, multifaceted approach, incorporating both conventional and nutritional strategies. Early recognition and intervention are essential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results